Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
about
Recent developments in the management of germ cell tumors.Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome.
P2860
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
description
im August 2016 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 24 March 2016
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2016
@uk
name
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
@en
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
@nl
type
label
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
@en
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
@nl
prefLabel
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
@en
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
@nl
P2093
P50
P1476
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
@en
P2093
Alessandro M Gianni
Daniele Raggi
Domenico Magazzù
Elena Togliardi
Elisa Coradeschi
Flavio Crippa
Patrizia Giannatempo
Pinuccia Valagussa
Raffaella De Fato
P304
261-264.e4
P356
10.1016/J.CLGC.2016.03.020
P407
P50
P577
2016-03-24T00:00:00Z